Abbott loses $1.67B patent fight to J&J

It's the patent judgment to end all patent judgments. A federal jury in Texas said Abbott Laboratories should pay some $1.7 billion to Johnson & Johnson for copycatting its blockbuster rheumatoid arthritis drug Remicade. J&J's Centocor subsidiary had alleged that Abbott's Humira was made with technology J&J exclusively licensed from New York University.

Abbott, however, argued that Humira is its own animal--literally. Rather than deriving the drug partly from mouse DNA, as Remicade is, Abbott made it entirely with human DNA, the company claims.

Both drugs are big-time sellers for their respective companies. Humira brought some $4.5 billion for Abbott last year, accounting for 15 percent of its revenues, while Remicade delivered some $1 billion to J&J's top line just during the first quarter of 2009.

"We are particularly gratified that the jury recognized our valuable intellectual property, finding our patent both valid and infringed," Centocor President Kim Taylor said in a statement. But Abbott says the fight's not over yet. An Abbott spokesman told the Chicago Tribune, "We are disappointed in this verdict, and we are confident in the merits of our case and that we will prevail on appeal."

- see the news from J&J
- check out the story from the Tribune
- get more from the Wall Street Journal

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.